NVS vs SLS
NVS: Global pharmaceutical and biotechnology company pioneering disease-modifying treatments across oncology, immunology, neuroscience, and rare genetic diseases. SLS: A late-stage biotech developer of WT1-targeting cancer immunotherapies and selective CDK9 inhibitors for various hematologic and solid tumor indications.
Side-by-side fundamentals
| Metric | NVS | SLS | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $156.11 | $10.84 | |
| Market cap as of 2026-08-03 | $232.1B | $2.0B | |
| P/E as of 2026-08-03 | 22.53 | n/a | |
| PEG as of 2026-08-03 | 3.66 | n/a | |
| Net margin as of 2026-08-03 | +22.5% | -736.2% | NVS higher |
| Gross margin as of 2026-08-03 | +75.0% | +93.1% | SLS higher |
| Operating margin as of 2026-08-03 | +29.9% | -730.7% | NVS higher |
| ROE as of 2026-08-03 | +29.9% | -47.1% | NVS higher |
| ROA as of 2026-08-03 | +11.1% | -42.6% | NVS higher |
| Debt / equity as of 2026-08-03 | 1.18 | 0.00 | SLS lower |
| Revenue growth (YoY) as of 2026-08-03 | +3.3% | n/a | |
| Dividend yield as of 2026-08-03 | +2.9% | n/a | |
| Beta as of 2026-08-03 | 1.17 | 2.50 | |
| 1-year return as of 2026-07-27 close | +32.6% | +502.2% | SLS higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.